Skip to main content
Top
Published in: Annals of Hematology 2/2004

01-02-2004 | Case Report

Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab

Authors: E. M. Buda-Okreglak, J. J. Drabick, N. R. Delaney

Published in: Annals of Hematology | Issue 2/2004

Login to get access

Abstract

Acute adverse reactions to rituximab treatment have been previously described in association with initiation of therapy. We describe a novel delayed proinflammatory syndrome which occurred at, or near, the completion of a 4-week dose-intense course with rituximab in a 58-year-old man with Waldenstrom's macroglobulinemia, and which mimicked acute rheumatoid arthritis affecting the hands and the knees. This syndrome was associated with an increase in acute phase reactants, and the clinical symptoms were temporally reproducible, although decreased in severity, with subsequent rituximab therapy, and each time responded to prednisone. This is the first report on an acute rheumatoid-like flare occurring in association with rituximab therapy. This phenomenon is all the more intriguing in that rituximab has been used to treat refractory rheumatoid arthritis. Potential etiologic mechanisms and management of this newly described phenomenon are discussed.
Literature
1.
go back to reference Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791–795PubMed Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 17:791–795PubMed
2.
go back to reference Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754–758CrossRefPubMed Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99:754–758CrossRefPubMed
3.
go back to reference Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135–3143PubMed Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R (2000) Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18:3135–3143PubMed
4.
go back to reference Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68–69CrossRef Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68–69CrossRef
5.
go back to reference De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029–2033CrossRefPubMed De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029–2033CrossRefPubMed
6.
go back to reference Edwards JC, Leandro MJ, Cambridge G (2002) B-lymphocyte depletion in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 30:824–828PubMed Edwards JC, Leandro MJ, Cambridge G (2002) B-lymphocyte depletion in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans 30:824–828PubMed
7.
go back to reference Jensen M, Winkler U, Manzke O, Diehl V, Engert A (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 77:89–91CrossRefPubMed Jensen M, Winkler U, Manzke O, Diehl V, Engert A (1998) Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 77:89–91CrossRefPubMed
8.
go back to reference Jeyarajah DR, Thistlethwaite HR Jr (1993) General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 25 [Suppl 1]:16–20 Jeyarajah DR, Thistlethwaite HR Jr (1993) General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 25 [Suppl 1]:16–20
9.
go back to reference Kelaidi C, Tulliez M, Lecoq-Lafon C, Pham X-V, Kahan A, Dreyfus S, Bouscany D (2002) Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. Leukemia 16:2173–2174CrossRefPubMed Kelaidi C, Tulliez M, Lecoq-Lafon C, Pham X-V, Kahan A, Dreyfus S, Bouscany D (2002) Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. Leukemia 16:2173–2174CrossRefPubMed
10.
go back to reference Leandro MJ, Edwards JCW, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888CrossRefPubMed Leandro MJ, Edwards JCW, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61:883–888CrossRefPubMed
11.
go back to reference Lim LC, Koh LP, Tan P (1999) Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 17:1962–1963 Lim LC, Koh LP, Tan P (1999) Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 17:1962–1963
12.
go back to reference Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W (2001) Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 60:892–893PubMed Stewart M, Malkovska V, Krishnan J, Lessin L, Barth W (2001) Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. Ann Rheum Dis 60:892–893PubMed
13.
go back to reference Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167:4710–4718PubMed Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167:4710–4718PubMed
14.
go back to reference Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanoulides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC (2001) The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. J Immunother 24:272–279CrossRef Treon SP, Agus DB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanoulides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC (2001) The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. J Immunother 24:272–279CrossRef
15.
go back to reference Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217–2224PubMed Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217–2224PubMed
Metadata
Title
Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab
Authors
E. M. Buda-Okreglak
J. J. Drabick
N. R. Delaney
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 2/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0747-5

Other articles of this Issue 2/2004

Annals of Hematology 2/2004 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.